The Moffitt Cancer Center today said findings from a study presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago further validated that Vidaza (azacitidine) significantly extends overall survival for patients with myelodysplastic syndromes (MDS) compared with conventional care regimens (CCR).
Based on this study, investigators have concluded that achieving complete remission is not obligatory for extending survival in higher-risk MDS patients.
In the study, patients who received Vidaza versus those who received conventional care had higher one-year survival rates in all response categories including partial remission, stable disease and haematologic improvement, without necessarily achieving complete remission.
“This study reinforces the role Vidaza plays in the treatment for MDS patients, helping to change what was previously an incurable blood cancer into a chronic, manageable disease,” said Dr Alan List of the Moffitt Cancer Center.
Vidaza is the first and only epigenetic therapy, a new class of anticancer compounds which can change the regulation of gene expression, to have demonstrated a survival benefit in any cancer.